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ABSTRACT 
 
Effects of Intra-Articular Lipopolysaccharide Injection on Systemic Cytokine Gene 
Expression and Leukocyte Population in Young Horses. (December 2011) 
Carrie Lynn Mueller, B.S., University of Wisconsin-River Falls 
Co-Chairs of Advisory Committee: Dr. Dennis Sigler 
 Dr. Josie Coverdale 
 
Nineteen yearling Quarter Horses were utilized in a randomized, complete block 
design to evaluate systemic cytokine gene expression and circulating leukocyte 
population in young horses following an intra-articular lipopolysaccharide (LPS) 
challenge.  Horses were administered an injection of 0.25 ng (n = 7) or 0.50 ng (n = 6) of 
LPS or lactated Ringer′s solution (n = 6; control).  Blood was collected via jugular 
catheter at pre-injection h 0 and at 2, 6, 12, and 24 h following aseptic injection of the 
left radiocarpal joint.  Aseptic arthrocentesis was performed at the same times to sample 
synovial fluid for a companion study.  Total RNA was isolated from leukocytes using a 
commercially available kit and real-time PCR was used to determine relative gene 
expression of the cytokines; interleukin (IL)-1beta (β), IL-6, IL-8, IL-10, and tumor 
necrosis factor-alpha (TNF-α).  Determination of total leukocyte subpopulations and 
differentials was performed by Texas Veterinary Medical Diagnostic Laboratory.   
Data were analyzed using the PROC MIX procedure of SAS.  Gene expression 
of all cytokines analyzed was unaffected by treatment.  However, changes over time 
were observed in some cytokines.  Interleukin-1β was increased above baseline at 6, 12, 
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and 24 h (P = 0.04), IL-6 was decreased slightly at 6 and 12 h and then increased at 24 h 
(P = 0.002), and TNF-α was increased at 6 and 12 h (P = 0.01).  Only IL-8 exceeded a 2-
fold change in expression (P = 0.01), peaking at 12 h and indicating greater 
responsiveness to arthrocentesis than was observed in the other cytokines.  No treatment 
effects on the leukocyte population were observed; however, total circulating leukocytes 
increased over time (P = 0.04), peaking at 6 h post-injection. Similarly, an increase over 
time was observed in monocytes (P = 0.002) and in platelets (P = 0.01) at 24 h post-
injection.  
The results indicate that regardless of treatment, a mild immune response was 
elicited, likely due to repeated arthrocentesis. Future experiments should consider the 
effects of arthrocentesis and potential systemic inflammatory response, even in control 
animals, when administering intra-articular LPS to young horses. 
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CHAPTER I 
INTRODUCTION 
 
Osteoarthritis and associated musculoskeletal injuries are commonly accepted as 
the most prevalent source of lameness in the equine athlete.  From an epidemiological 
standpoint, joint disease has been deemed the primary source of inferior performance 
and inability to compete in the racehorse (Jeffcott et al., 1982; Wilsher et al., 2006).  In 
one study, of 1,042 horses admitted to a large animal clinic for signs of lameness, 42% 
had lameness related to joint disease (Todhunter and Lust, 1990).  The economic impact 
of this loss of performance is significant and demonstrates the need for investigation of 
this condition.  Several experimental models have been developed such that the 
pathogenesis of joint disease may be studied as well as the effectiveness of potential 
treatment options.  Previous studies have included intra-articular injection of the polyene 
antibiotic, filipin (McIlwraith et al., 1979), sodium monoiodoacetate (Trotter et al., 
1989), and articular particles (Hurtig, 1988).  While useful, these models all utilize 
primary cartilage destruction and fail to investigate the effects of synovial membrane 
inflammation alone on articular cartilage metabolism.  
Intra-articular injection of Escherichia coli-derived lipopolysaccharide (LPS) has 
been used successfully as a method of inducing temporary inflammation in adult horses 
to mimic the progression of joint disease (Firth et al., 1987; Palmer and Bertone 1994;  
De Grauw et al., 2009).  While this model has been useful, to our knowledge the model  
____________ 
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has thus far been applied solely to skeletally mature horses.  Because the highest 
competitions in many performance disciplines such as futurities are limited to horses in 
their 3-year-old years, adolescent horses enter rigorous training regimens at an early age.  
The immature skeletal structure of a young horse in training is subject to repeated stress 
which induces inflammation and may ultimately lead to articular degradation.  Models 
for experimentally-induced inflammation designed for the mature horse may not be 
appropriate for the growing horse due to factors including differences in body size, 
biomechanical forces, and immunological development.  It has been suggested that the 
structures involved in osteoarthritis may be affected differently by trauma, degeneration, 
or osteochondrosis due to age (Goodrich and Nixon, 2006).  Thus, determining an 
appropriate dosage of LPS and establishing a model for investigating joint degradation 
in a horse at this stage of maturity would be beneficial. 
Previous studies have typically focused on biomarkers derived from synovial 
fluid to detect articular degradation.  While this approach is beneficial in providing 
insight into the current condition of a particular joint, this methodology fails to consider 
the overall health and immune status of the animal.  It is unknown whether a horse 
exhibiting signs of lameness may be experiencing a systemic inflammatory response.  If 
this is the case, management decisions should take into consideration this potential 
overstimulation of the immune system. 
Furthermore, the potential correlation between joint degradation and alterations 
in systemic biomarkers may provide a less invasive alternative for assessing the current 
status of joint health as well as providing early detection of complications prior to when 
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clinical signs become apparent.  Gene expression of pro-inflammatory cytokines derived 
from synovial fluid has been successfully used as an indirect marker of joint disease 
(Lipsky et al., 1989).  We hypothesize that analyzing the peripheral blood gene 
expression of a panel of cytokines known to be crucial mediators of the inflammatory 
response will enable determination of whether a systemic inflammatory response occurs 
in conjunction with a localized inflammatory insult.  Therefore, the objectives of the 
current study were to: 
1.) quantify and compare the total circulating leukocyte population and determine 
cellular differential; and  
2.) evaluate the peripheral blood gene expression of a panel of principal cytokines 
involved in the inflammatory cascade in yearling horses following an intra-articular LPS 
injection at different dosage levels. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
Anatomy of the Synovial Joint 
 The purpose of a synovial joint is to facilitate movement as well as disperse and 
transmit biochemical load.  Its structure consists of two or more articulating bone 
surfaces, articular cartilage, the joint cavity, and the joint capsule.  The capsule functions 
in conjunction with neighboring ligaments to maintain the proper position of the 
articular surfaces.  This capsule consists of a superficial avascular, fibrous layer (stratum 
fibrosum) and a deeper, secreting layer (stratum synoviale), also referred to as the 
synovial membrane.  The synovial membrane is a vascular connective tissue that 
secretes synovial fluid and contains synoviocytes, which perform phagocytosis and 
synthesize inflammatory mediators including prostaglandins, proteases, and interleukin 
(IL)-1 (Goodrich and Nixon, 2006).  The joint cavity refers to the space between the 
adjacent bones of the joint which is surrounded by the joint capsule.  This cavity is 
small, filled with synovial fluid, and is enclosed by the synovial membrane.  Synovial 
fluid is a lubricating fluid containing ions and molecules similar to those found in blood 
plasma, with the addition of a high concentration of hyaluronan.  Synovial fluid contains 
approximately 10% polymorphonuclear leukocytes with the remaining volume 
consisting of mononuclear cells (predominantly monocytes, lymphocytes, synovial 
lining cells; Helal and Karadi, 1968). 
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 A layer of hyaline cartilage known as articular cartilage covers the articular 
surface.  Its approximate composition is 75% water, 15% type II collagen, 10% 
proteoglycans, and 2% chondrocytes (Poole, 2001).  The type II collagen fibrils form a 
network containing proteoglycans and hyaluronan, which provide compressive stiffness 
and tensile strength to the articular cartilage.  The proteoglycans are actively turned over 
via synthesis by chondrocytes and degradation by extracellular proteinases, resulting in a 
delicate equilibrium.  Under normal conditions, the stringent regulation of this matrix 
homeostasis is achieved through cytokines, growth factors, and proteinases (Tyler, 
1991).   
Pathology of Osteoarthritis 
 Osteoarthritis is a degenerative, chronic disease which occurs when there is an 
imbalance of extracellular matrix destruction and repair and is characterized by erosion 
of type II collagen and cartilage-specific proteoglycans (Todhunter et al., 1996).  
Numerous causes of osteoarthritis have been implicated; however, the most prevalent 
cause in young horses is trauma and the concomitant synovitis (McIlwraith and Trotter, 
1996).  Repetitive overuse and deficiencies in conformation are contributing factors due 
to excessive biomechanical forces overwhelming the structural integrity of the legs.  The 
joints of the young horse, favoring tissue turnover and growth, have higher synthesis 
rates of total protein and stromelysin in articular cartilage as well as greater metabolic 
activity overall when compared with adult horses (Morris and Treadwell, 1994). 
 Typically, the inflammatory process is initiated in the synovial membrane, 
cartilage, or subchondral bone.  While the interactions between tissues are complex and 
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not fully understood, some traumatic event triggers the release of inflammatory 
mediators, principally cytokines IL-1 and TNF-α, from the primary tissue of insult.  
These cytokines inhibit proteoglycan synthesis and cause the release of 
metalloproteinases and prostaglandins from synoviocytes and chondrocytes (McIlwraith 
and Trotter, 1996).  In addition, IL-1 stimulates chondrocytes to secrete stromelysin, 
which cleaves collagenase to its active form (Towle et al., 1987).  Cysteine proteases, 
also released from the synovial membrane by IL-1 or TNF-α signaling, digest articular 
cartilage matrix, releasing degradative particles into the synovial fluid (Huet et al., 
1993).  Chondrocytes, synoviocytes, bone cells, and leukocytes release a host of pro-
inflammatory cytokines, which upregulate the activity of various metalloproteinases and 
signal for additional release of inflammatory mediators.  Collagenase is the principal 
proteinase involved, disturbing the triple helix structure and effectively disrupting the 
integrity of collagen tissue.   
This imbalance of metabolism results in a loss of proteoglycans and collagen 
from the articular matrix as well as the subsequent biomechanical failure and pain 
associated with osteoarthritis (Poole, 1990).  As degradation ensues, proteoglycan 
particles from the cartilage are released into the synovial fluid.  This exacerbates the 
progression of the disease as products of proteoglycan catabolism are antigenic and 
stimulate synovial inflammation (Glant et al., 1993).    
It is well recognized that with current technology, identifying early stages of 
cartilage degradation and resulting osteoarthritis is difficult and often impossible prior to 
the appearance of radiographic evidence.  Much research has been devoted to the 
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development of biomarkers which can be used to monitor degradative changes in the 
articular structures of the joint.  Cytokines, particularly IL-1 and TNF-α, are one such 
area under investigation for potential correlation between gene expression and 
inflammatory status of an individual.   
Cytokines 
Cytokine, also known as peptide regulatory factor, is an expansive term which 
encompasses the small, cell-signaling protein molecules secreted by various cells of the 
body, particularly those of the immune system.  Cytokines influence the function of a 
target cell by altering gene expression in a positive or negative manner.  The cytokine 
family includes the interleukins, lymphokines, and signaling molecules including tumor 
necrosis factor and the interferons.  These polypeptides are structurally diverse but 
possess many shared properties (O’Shea and Murray, 2008). 
 Cytokines are produced in response to inflammatory or antigenic stimuli and can 
exhibit local or systemic effects via autocrine, paracrine, or endocrine actions.  These 
proteins provide a crucial link between innate and adaptive immunity by mediating the 
immune responses of both systems.  Resting lymphocytes and other cell types of the 
immune system do not produce cytokines routinely (Lipsky et al., 1989).  Rather, 
synthesis of cytokines is generally induced by new gene transcription resulting from 
transient transcriptional activation.  The instability of encoding messenger RNA results 
in cytokine synthesis being transient as well.  Further control over cytokine production 
exists in RNA and proteolytic processing.  Upon synthesis, cytokines are secreted in a 
rapid surge (Abbas et al., 2010). 
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Circulating cytokines bind to specific transmembrane receptors which are 
regulated by external signals, such as B or T lymphocyte stimulation.  Other cytokines 
can also up- or down-regulate the expression of receptors.  Cytokines bound to the 
extracellular portion of the receptor initiate intracellular signaling pathways by altering 
gene expression in target cells.  Typical effects induced by cytokines include lymphocyte 
differentiation and activation of effector cells.  The secretion of cytokines triggers a 
cascade of events which has diverse effects on cells involved in immunity and 
inflammation.  Cellular responses are tightly regulated through negative feedback 
mechanisms and inhibitors, and signals are fine-tuned through the synergistic and 
antagonistic properties of cytokines (Abbas et al., 2010). 
The biomedical field has expressed an increasing interest in cytokine therapy as 
more is discovered about the mechanisms of action and effects of individual cytokines.  
Certain cytokines are commonly used as therapeutic agents as well as targets for 
antagonists in many inflammatory and immune diseases (Abbas et al., 2010).  A 
difficulty with this approach, however, is the pleiotropic and redundant tendencies of 
cytokines; treatment with one cytokine may have unintended additional effects, while an 
antagonist against one cytokine may not be effective due to compensation by other 
cytokines. The inflammatory cascade initiated by cytokine release is crucial to the 
pathological events that ensue, and thus understanding these events is fundamental to 
effectively disrupting the cascade and preventing damaging biochemical changes.   
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Tumor Necrosis Factor-alpha 
Tumor necrosis factor-alpha (TNF-α) is considered to be the primary mediator of 
the acute inflammatory response and is responsible for systemic complications derived 
from serious infections.  TNF-α is primarily secreted by activated mononuclear 
phagocytes; however, additional sources include antigen-stimulated T cells, natural killer 
cells, and mast cells.  The strongest stimulus for macrophage secretion of TNF-α is the 
interaction of Toll-like receptors with LPS and other microbial products (Abbas et al., 
2010).  Natural killer cells and T lymphocytes produce interferon-gamma, which 
amplifies TNF-α production by LPS-stimulated macrophages.  Activation and 
recruitment of neutrophils and monocytes to sites of infection are the primary roles of 
TNF-α.  This is accomplished through a variety of actions.  Tumor necrosis factor-α 
stimulates chemokine production by macrophages, which generates leukocyte 
chemotaxis and recruitment.  Additionally, TNF-α initiates IL-1 secretion, induces 
apoptosis, and stimulates endothelial cells to produce adhesion molecules for leukocyte 
accumulation.  When acute trauma is severe, TNF-α is produced in substantial quantities 
and causes systemic pathologic anomalies (Abbas et al., 2010).  Séguin and Bernier 
reported that TNF-α disrupts the synthesis of articular cartilage matrix and glycoproteins 
during inflammation by down-regulating link protein and type II collagen formation at 
the transcriptional level (2003).   
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Interleukin-1 
Many of the cytokines which are synthesized by leukocytes and exhibit their 
effects on leukocytes are classified as interleukins.  Interleukin-1 exists in two isoforms 
(alpha and beta) and is released from a multitude of cells including macrophages, 
neutrophils, epithelial cells, and endothelial cells.  However, the largest amounts of IL-1 
seem to be released from mononuclear phagocytic cells at sites of inflammation (Lipsky 
et al., 1989).  It is typical for these cells to store large amounts of IL-1 in the cytoplasm, 
ready for release upon stimulation.  While sharing less than 30% amino acid homology, 
IL-1α and IL-1β appear to share the same surface receptor and have similar biologic 
activities (Auron et al., 1984).  Equine IL-1 produced from peripheral blood monocytes 
stimulated with LPS has been identified as the equine form of IL-1β (May et al., 1990).  
Both equine IL-1α and IL-1β inhibit proteoglycan synthesis of articular cartilage 
explants (Takafuji et al., 2002).  The IL-1β precursor is inactive and must be cleaved 
enzymatically, which is likely the rate-limiting step in IL-1 secretion (Dinarello, 1989).  
This cytokine works in conjunction with TNF-α to mediate the host inflammatory 
response.  It also stimulates the secretion of other inflammatory cytokines including IL-2 
and IL-6 and induces cytokine receptors to be expressed on T cells and hemopoietic 
stem cells (Dinarello, 1989).     
Extensive research implicates TNF-α and IL-1 as the key mediators in the 
progression of joint disease.  Numerous in vitro studies support the notion that these 
cytokines work synergistically with almost identical effects, stimulating proteinase 
synthesis by chondrocytes and production of neutral metalloproteinases (Dinarello, 
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1986; Ratcliffe et al., 1986; Loyau and Pujol, 1990).  Injection of IL-1 into the knee 
joints of mice stimulates in vivo proteoglycan degradation and inhibits resynthesis (van 
Beuningen et al., 1991).   
Interleukin-6 
 Another cytokine integral to both innate and adaptive immunity is IL-6.  The 
presence of microbes, IL-1, and TNF-α stimulate synthesis of IL-6 by cells including 
mononuclear phagocytes, endothelial cells, and fibroblasts.  Interleukin-6 contributes to 
the acute-phase response by inducing synthesis of hepatic acute-phase proteins and 
stimulating neutrophil production from bone marrow progenitors.  Stimulating B 
lymphocytes and pro-inflammatory cytokine production, serving as a growth factor for 
myeloma cells, and inhibiting regulatory T cells are additional attributes of IL-6 (Abbas 
et al., 2010).  High synovial fluid concentrations of IL-6 have been reported in an equine 
severe joint disease model (Bertone et al., 2001) as well as in humans with progressive 
rheumatoid arthritis (Kutukculer et al., 1998).   
Interleukin-8 
 Interleukin-8 is classified as a chemotactic cytokine, or chemokine.  Its primary 
purpose is to induce chemotaxis in neutrophil granulocytes.  Interleukin-8 functions as a 
mediator of the innate immune system and is secreted by cells with toll-like receptors.  
Production of IL-8 has been reported in vitro in LPS-stimulated macrophages, 
endothelial cells, and fibroblasts (Larsen et al., 1989).  A synovial fluid source of this 
cytokine has not been demonstrated (Lipsky et al., 1989), thus its potential effects in the 
peripheral blood merit investigation. 
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Interleukin-10 
Interleukin-10 is an important cytokine in the anti-inflammatory cascade and is 
produced chiefly by macrophages as well as regulatory T lymphocytes.  The primary 
role of IL-10 is to inhibit the pro-inflammatory effects of activated macrophages, mainly 
by down-regulating reactions which produce inflammatory products such as IL-12, 
interferon-gamma, and class II major histocompatibility complex (MHC) surface 
molecules.  Interleukin-10 impairs the activation of T lymphocytes and abolishes cell-
mediated immune reactions, limiting and ultimately terminating inflammatory reactions.  
The TNF-α-induced release of prostaglandin E2, a crucial mediator of inflammation, is 
also impeded by IL-10 (Alaaeddine et al., 1999).  Consequently, IL-10 is considered to 
be a critical signal for the regulation of both innate and cell-mediated inflammatory 
responses. 
Synovial Fluid Cytokines as Biomarkers for Joint Disease 
Previous work has largely relied upon biomarkers within the synovial fluid to 
assess joint condition.  Cytokines are crucial mediators of the inflammatory response, 
and pro-inflammatory cytokines have been used widely as indirect markers of joint 
disease (Lipsky et al., 1989).  In a study evaluating the usefulness of several synovial 
fluid cytokines to detect, diagnose, and characterize joint disease, it was found that IL-6 
was an excellent marker, being both sensitive and specific; presence of synovial fluid IL-
6 indicated joint disease and was highly correlated to synovial fluid leukocyte counts 
(Bertone et al., 2001).  The same study, which used ELISAs on synovial fluid samples 
from 119 joints, identified TNF-α and IL-1β as good predictors of joint disease (Bertone 
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et al., 2001).  All three of these cytokines have been determined to be fundamentally 
involved in stimulating an acute inflammatory response (Molloy et al., 1993) as well as 
synovial metabolism, joint inflammation, and stimulating articular cartilage degradation 
(Shinmei et al., 1989).  Studies have reported increased expression of IL-1β and TNF-α 
in the synovial fluid of osteoarthritic horses (Alwan et al., 1991; Hawkins et al., 1993), 
indicating their usefulness as secondary biomarkers of joint degradation. 
The anti-inflammatory cytokines detected at increased levels in synovial fluid of 
osteoarthritic joints are IL-4, IL-10, and IL-13 (Sutton et al, 2009).  An in vitro study 
investigating LPS-stimulated human monocytes reported the production of high levels of 
IL-10, which strongly inhibited the expression of IL-1α, IL-1β, IL-6, IL-8, TNF-α, and 
granulocyte colony-stimulating factor (de Waal Malefyt et al., 1991).  This inhibition has 
been reported to be similar in both the synovial fluid and peripheral blood mononuclear 
cells (Hart et al., 1995).   
Systemic Cytokine Response to Intravenous LPS Infusion 
To our knowledge, cytokine expression in equine plasma has not been measured 
in response to an intra-articular LPS challenge.  However, LPS has been alternatively 
introduced in several studies investigating equine response to endotoxin.  MacKay and 
colleagues (1991) identified TNF as a critical early mediator in the cellular response to 
LPS based on its effects on cytotoxicity in an in vitro study.  Inflammatory cytokine 
expression has also been evaluated in peripheral blood of horses following an 
intravenous infusion of LPS.  Up-regulation of IL-1α, IL-1β, IL-6, IL-8, and TNF-α was 
quantified by real-time PCR, with expression peaking at 60 min (IL-1α, IL-1β, IL-6, and 
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TNF-α) and 90 min (IL-6) post-infusion (Nieto et al., 2009).  A similar increase in serum 
IL-1β, IL-6, and TNF-α was reported in intra-arterially LPS-challenged rats (Givalois et 
al., 1994).  Lipopolysaccharide appears to reliably induce a detectable alteration in gene 
expression of several cytokines involved in the inflammatory cascade. 
Intra-Articular Injection of LPS to Induce Acute Inflammation 
LPS Structure 
Previous studies in numerous species have utilized intra-articular LPS injection 
to induce temporary inflammation.  As the name indicates, LPS is a molecule consisting 
of a polysaccharide covalently-linked to a lipid moiety.  An O-specific chain and core 
oligosaccharide are anchored in the outer bacterial membrane and attached to lipid A, 
which is a phosphorylated glucosamine disaccharide linked to several fatty acids.   The 
Lipid A portion is responsible for the endotoxic effects of LPS (Silipo et al., 2002; 
Figure 1). 
 
 15 
 
Figure 1. Lipid A structure of Escherichia coli (Adapted from Silipo et al., 2002).   
GlcN = glucosamine. 
 
Lipopolysaccharide is a major structural component of the cell wall of gram-
negative bacteria and acts as a strong endotoxin.  Its ability to elicit in vivo cartilage 
degradation has been previously demonstrated in horses (De Grauw et al., 2009) and 
rabbits (Sáez-Llorens et al., 1991).  In vitro studies have produced similar effects in 
cartilage of equine (Todhunter et al., 1996), bovine (Morales et al., 1984), and canine 
(Todhunter et al., 1995) species.  Lipopolysaccharide is recognized by Toll-like receptor 
4, which activates macrophages to release cytokines (principally TNF, IL-1, and IL-6) 
and initiate an inflammatory cascade (Warren et al., 2010).  The primary cytokine 
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released in response to LPS is TNF-α, which then stimulates the release of a number of 
products from macrophages and initiates the cascade of events which may ultimately 
lead to septic shock or death (Mathison et al., 1988).  
Previous Studies Utilizing Intra-Articular LPS 
Hawkins et al. (1993) reported that injection of 3 μg of LPS into the 
antebrachiocarpal joint of horses resulted in signs of acute synovitis (increased surface 
temperature of LPS-injected carpi, increased synovial fluid leukocyte count, increased 
prostaglandin E2) within 2 h of injection.  These findings are in agreement with Jacobsen 
et al. (2006), who reported fever, tachycardia, tachypnea, acute lameness, and joint 
swelling within 4-8 h following 1 μl and 3 μl LPS injection.  An even larger dosage of 
0.1 μg of LPS/kg has elicited acute fever, depression, increased pulse and respiratory 
rates, and lameness in ponies (Firth et al., 1987).  Palmer and Bertone (1994) sought to 
compare dosage levels of 0.125 ng, 0.17 ng, 0.25 ng, 0.5 ng, 25 ng, and 5,000 ng of LPS 
per joint in adult horses.  The authors reported signs of endotoxemia (i.e., fever, 
depression, lack of appetite, severe lameness) at doses larger than 0.5 ng per joint 
(Palmer and Bertone 1994).  At 12 h post-LPS injection, the magnitude of systemic signs 
presented by these horses required that they be treated with phenylbutazone and 
excluded from the remainder of the study. 
The dosage of 0.5 ng LPS successfully altered markers of collagen II turnover 
(collagenase cleavage neopeptide and carboxypeptide) and inflammatory mediators 
(prostaglandin E2, substance P, and bradykinin) when injected into the midcarpal joint of 
adult horses (De Grauw et al., 2009).  These data suggest that investigation of varying 
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dosage levels is warranted, specifically for the target population of adolescent equines, 
which has thus far been largely underrepresented in studies of equine joint health.  
Ideally, the lowest effective dosage that elicits detectable joint inflammation should be 
employed.  This is to minimize discomfort to the experimental subject as well as to more 
accurately mimic the pathophysiology of equine joint disease.  While injection of large 
doses of LPS elicits rapid, significant changes, these models represent a severe arthritis 
or acute joint sepsis.  A model which induces a less severe synovitis would more 
accurately mimic the progression of joint disease in a typical clinical case and thus may 
prove more beneficial for making inferences about the development of osteoarthritis and 
developing preventative strategies to combat early progression of the disease.   
In addition, it is of note that studies of this nature often treat each experimental 
animal with intra-articular LPS, utilizing the contralateral joint as a saline-injected 
control (Hawkins et al., 1993; De Grauw et al., 2009).  This may be of importance, as an 
earlier study has reported signs of synovitis, enhanced cytokine immunoreactivity, and 
cartilage degradation in the saline-injected, contralateral joint of horses injected with 
LPS (Todhunter et al., 1996).  These findings are in agreement with studies which have 
observed loss of proteoglycans in the saline-injected joint contralateral to either the 
hyaluronate-polylysine-injected joint in rabbits (Smith et al., 1994) or the IL-1-injected 
joint in rats (Chandrasekhar et al., 1992).  Saline solution injections did not appear to 
directly cause proteoglycan loss, as control animals treated with saline alone experienced 
no alterations in proteoglycan content (Smith et al., 1994).  Rather, these results suggest 
a potential systemic effect induced by the inflammatory agent.  It is possible that 
 18 
cytokine-producing leukocytes may have been recruited and released into circulation, 
ultimately reaching the contralateral joint and altering proteoglycan metabolism at this 
site as well as the primary site of insult.  Alterations in serum concentrations of a direct 
indicator of the predominant protein in cartilage (N-propeptide of type IIA procollagen) 
have been reported in human osteoarthritic patients, indicating that systemic effects are 
generated by the disease (Garnero et al., 2002).  Due to the potential for unintended 
systemic consequences, an investigation into the effects of a singular intra-articular 
challenge utilizing appropriate controls is clearly warranted. 
Conclusion 
In summary, osteoarthritis is a prevalent disease which contributes profound 
losses to the performance horse industry.  The mechanisms of the disease are poorly 
understood, and a reliable early detection method has not been developed.  Current 
models for the disease utilize the adult horse; however, a young horse model may be 
more appropriate due to industry standards placing high physical demands on skeletally 
immature horses.  While numerous studies have utilized primary cartilage destruction to 
investigate the pathophysiology of osteoarthritis, synovial inflammation has been largely 
ignored.  However, research suggests that inflammatory cytokines are crucial bio-
signaling molecules which have a large role in the development of osteoarthritis by 
stimulating chondrocytes and synoviocytes to secrete cartilage-degrading proteinases.  
The use of these proteins as biomarkers may provide a more practical, less invasive 
means of monitoring joint health and identifying individuals at risk for development of 
osteoarthritis.  Reported systemic alterations in response to both osteoarthritis and a 
 19 
single inflammatory insult merit the use of a separate group of control animals, a 
measure not typically practiced in prior studies.  Therefore based on previous literature, 
a study utilizing a young horse model to investigate the potential systemic effects of a 
single, intra-articular challenge with separate control animals may provide valuable 
insight on the metabolic response to synovial inflammation in the young horse.   
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CHAPTER III 
MATERIALS AND METHODS 
 
All procedures were approved by the Texas A&M University Institutional 
Animal Care and Use Committee (AUP #2010-221).   
Animals and Treatments 
Nineteen yearling Quarter Horses from the Texas A&M University Horse Center 
herd were utilized in a randomized, complete-block design.  Horses were of similar 
breeding and aged 184 to 327 d with initial BW ranging from 220 to 384 kg.  Horses 
were blocked by age, sex, and BW and randomly assigned within block to one of three 
treatments.  Treatments were an injection containing 0.25 ng (n = 7) or 0.5 ng (n = 6) of 
LPS or lactated Ringer′s solution (n = 6; control).  The LPS was obtained from E. coli 
055:B5 and diluted in sterile lactated Ringer’s solution to the desired concentration.   
 Horses were housed in groups of four or five by BW in 25 m x 25 m dry lots for 
a back-grounding period of 21 d prior to the start of the study.  Throughout the 
experiment horses were group fed by pen and received approximately 1% BW (as fed) 
of a commercially prepared pelleted concentrate (Producers 14% Horse Pellet, 
Producer’s Cooperative Association, Bryan, TX; Table A.1) and 1.5% BW (as fed) of 
Coastal Bermudagrass hay (Cynodon dactylon; Table A.1), divided into two daily 
feedings.  Biweekly BW measurements were determined using a digital platform scale 
(CAS Corp. Seoul, Rep. of Korea) and diets were adjusted accordingly.  Horses were 
provided free access to water at all times.  Throughout the back grounding period horses 
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were individually handled a minimum of two times per week to mimic procedures used 
throughout the LPS challenge, with activities including being haltered, standing tied, 
leading quietly at the walk and trot, walking across the scale, and picking up both front 
feet.   
LPS Challenge (Time 0) 
On the day of the LPS challenge, horses were individually confined in 3 m x 3 m 
stalls and had a 14-gauge catheter inserted aseptically in the left jugular vein following 
subcutaneous administration of 1.5 ml sterile lidocaine hydrochloride 2% (RXV 
Products, Westlake, TX).  Catheters were maintained every 2 h throughout the sampling 
period with 6 ml of heparinized saline solution.  Horses were unobtrusively monitored 
for at least 2 h following catheter placement prior to sample collection.  Subsequently, 
time 0 was established, and heart rate (HR) and respiratory rate (RR) were recorded as 
well as rectal temperature via thermometer.  Each horse was then removed from its stall 
and trotted in-hand across the concrete barn-aisle for determination of a lameness score, 
according to the American Association of Equine Practitioners’ (AAEP) lameness 
grading system (range 0-5, with 0 assigned to horses with no detectable lameness and 5 
for non-weight bearing lameness; AAEP 1999).  The same evaluators scored all 19 
horses for consistency.  Circumference of the left carpal joint, which had been clipped 
24 h prior, was measured in centimeters using a flexible measuring tape at the level of 
the accessory carpal bone by a single observer.  The carpus was prepared immediately 
prior to arthrocentesis by scrubbing the surface, alternating diluted Betadine scrub and 
70% isopropyl alcohol.  A licensed veterinarian from the Texas A&M University Large 
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Animal Clinic (College Station, TX) performed arthrocentesis of the left radiocarpal 
joint, extracting synovial fluid samples with a 20-gauge needle and 6-ml syringe.  
Synovial fluid samples were processed for analysis of markers of joint inflammation and 
cartilage markers in a related study (Lucia et al., 2011).  Immediately following synovial 
fluid aspiration, 0.8 ml was injected into the same joint containing LPS according to 
assigned treatments.    
Blood Sampling 
Subsequently, blood was collected via the jugular catheter into 
ethylenediaminetetraacetic acid (EDTA)-containing evacuated tubes (Kendall Co., 
Mansfield, MA).  Air-dried, unstained blood-smear slides were prepared from each 
sample and accompanied chilled blood collection tubes which were promptly transported 
to the Texas Veterinary Medical Diagnostic Laboratory (College Station, TX) for 
analysis.  Total leukocyte population was determined using a hematology analyzer 
(Abbott CELL-DYN 3700, Global Medical Instrumentation, Inc., Ramsey, MN) and 
differentials were determined manually.  An additional 8 to 10 ml peripheral blood 
sample collected into tubes containing EDTA was passed through a LeukoLOCK™ 
filter
1
 to capture the total leukocyte population for later gene expression analysis.  Filters 
were flushed with 3 ml of phosphate-buffered saline (PBS) to remove residual red blood 
cells and 3 ml of RNAlater™ solution1 to stabilize RNA.  Stabilized filters were stored 
at room temperature for 24 h, at which point trapped leukocytes were lysed with 2.5 ml 
of LeukoLOCK™ lysis/binding solution1 and the lysate was collected in 15-ml conical  
____________ 
1
 Ambion Inc, Austin, TX 
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tubes and stored at -80°C until further analysis. 
Post-Injection Hours 2, 6, 12, 24 
Horses were maintained in stalls under constant supervision for the 24 h duration 
of the sample collection period.  Determination of vital signs, lameness scores, joint 
circumference, and synovial fluid collection occurred at 2, 6, 12, and 24 h post-injection 
of LPS.   
Laboratory Analysis 
RNA Isolation 
RNA-containing lysate was thawed at 23°C and RNA was extracted from the 
total leukocyte population using a commercial system (LeukoLOCK™ Total RNA 
Isolation System, Ambion Inc, Austin, TX) following the manufacturer’s protocol.  
Briefly, nuclease-free water was added to each tube along with proteinase K and 
incubated for 5 min at 23°C with intermittent inversion to degrade cellular proteins.  
Isopropyl alcohol (100%) and 50 μl of RNA binding beads were added to each tube, 
mixed, and incubated at 23°C with intermittent mixing for 5 min to allow RNA to bind 
to the beads.  Beads were pelleted using a centrifuge at 2,000 x g for 3 min (5810R, 
Eppendorf North America, Westbury, NY).  Supernatant was aspirated and discarded.  
Beads were then washed twice with a wash solution and transferred to a 1.5-ml 
microcentrifuge tube.  Samples were spun in a centrifuge (5415C, Eppendorf North 
America, Westbury, NY) at 16,000 x g for 30 s to pellet the beads and supernatant was 
discarded upon aspiration.  A second wash solution was added, followed by brief 
centrifugation and aspiration as described.  An optional DNase treatment included with 
 24 
the kit was then performed.  A master mix of DNase and a buffer solution was added to 
each tube, which was then agitated gently for 10 min at 23°C to release nucleic acids 
from RNA binding beads and degrade genomic DNA.  Lysis/binding solution and 100% 
isopropyl alcohol were added and tubes were incubated at room temperature for 3 min.  
Two further cycles of centrifugation, aspiration, and washing steps were repeated.  
Following the final aspiration, tubes were left open at room temperature for 3 min to 
allow residual liquid to evaporate.  Approximately 150 μl of an elution solution was 
added to the tubes which were then mixed vigorously for 30 s.  A final centrifugation at 
16,000 x g for 2 min pelleted the beads, and the RNA-containing supernatant was 
aspirated and transferred to a microcentrifuge tube and stored at -20°C. 
Treatment for DNA Contamination 
Nucleic acid concentration and purity were assessed using a micro-volume 
spectrophotometer (NanoDrop 1000, Thermo Scientific, Wilmington, DE).  Samples 
were treated to remove residual contaminating DNA using a commercial kit (TURBO 
DNA-free™ Kit, Ambion Inc, Austin, TX) using the manufacturer’s protocol.  Briefly, 
15 μl of provided 10X DNase Buffer and 1 μl DNase were added to each 
microcentrifuge tube containing RNA and gently mixed.  Following 20 min incubation 
at 37°C, 16.6 μl of resuspended DNase Inactivation Reagent was added.  The tubes were 
mixed thoroughly and incubated 5 min at 23°C.  Finally, tubes were centrifuged at 
10,000 x g for 1.5 min.  Purified RNA was transferred to a fresh tube and nucleic acid 
concentration and purity were reassessed by spectrophotometry.  Samples were then 
stored at -20°C until further analysis. 
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cDNA Synthesis 
 DNase/RNase-free distilled H20 was used to dilute samples such that each aliquot 
contained 500 ng of RNA and had a final volume of 10 μl.  Synthesis of cDNA was 
performed using the SuperScript III First-Strand Synthesis System for RT-PCR 
(Invitrogen Corporation, Grand Island, NY) following the manufacturer’s instructions.  
Briefly, 2 μl of cDNA first-strand mix consisting of equal parts oligo (dT)20 and dNTPs 
were added to each tube and mixed gently.  Tubes were incubated on a thermal cycler at 
65°C for 5 min, then at 4°C for at least 1 min.  A cDNA master mix was prepared and 10 
μl were added to each reaction, followed by incubation on the thermal cycler at 50°C for 
50 min, then at 85°C for 5 min.  Subsequently samples were diluted with 28 μl nuclease-
free water so that the final concentration of cDNA was 10 ng/μl and aliquots were stored 
at -80°C. 
Primer and Probe Sequences 
Previously designed equine-specific sequences for B2M, IL-6, and IL-8 were 
used (Nerren, 2008) as well as for IL-10 (J. Nerren, unpublished data).  Specific primer-
probe premixes were designed for equine TNF-α and IL-1β using the Assays-by-Design 
software program (Applied Biosystems, Foster City, CA).  All sequences are listed in 
Table 1. 
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Real-Time PCR 
 Quantitative real-time polymerase chain reaction (PCR) was carried out in 10-μl 
reactions, each containing 1 μl template cDNA and 5 μl TaqMan Universal Master Mix 
II (Applied Biosystems, Foster City, CA).  The remaining volume consisted of either 0.5 
μl primer-probe premix and 3.5 μl nuclease-free water (Invitrogen Corporation, Grand 
Island, NY; TNF-α, IL-1β), or 0.45 μl of each primer, 0.5 μl probe, and 2.6 μl water 
(B2M, IL-6, IL-8, IL-10).  A GeneAmp 7500 Sequence Detection System was used for 
all cDNA amplification and data analysis (Applied Biosystems, Foster City, CA).  The 
thermal profile consisted of an initial hold at 50ºC for 2 min, followed by denaturation at 
95°C for 10 min, then 40 cycles of 95°C for 15 s, 60°C for 60 s.  
 Beta-2 Microglobulin (B2M) served as the endogenous control and was used to 
normalize all resulting cycle threshold (Ct) values.  Target genes were calibrated to 
baseline expression (Time 0) and relative expression levels were determined using the   
2
-ΔΔC
T method of quantification (Livak and Schmittgen, 2001). 
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Table 1. Oligonucleotide primer and probe sequences for equine cytokine targets and 
endogenous control. 
Gene  Primer/probe Sequence (5’-3’) 
B2M* 
 
Forward 
Reverse 
Probe 
CGGGCTACTCTCCCTGACT 
GGGTGACGTGAGTAAACCTGAAC 
CCGTCCCGCGTGTTC 
   
IL-1β Forward 
Reverse 
Probe 
GAATGACCTGTTCTTTGAGGAGGAT 
GAGCTGAGGTCCAGGTCTTG 
AAGCTGCCCTTCATCTGT 
   
IL-6* Forward 
Reverse 
Probe 
GAAAAAGACGGATGCTTCCAATCTG 
TCCGAAAGACCAGTGGTGATTTT 
CAGGTCTCCTGATTGAAC 
   
IL-8* Forward 
Reverse 
Probe 
GCCACACTGCGAAAACTCA 
GCACAATAATCTGCACCCACTTTG 
ACGAGCTTTACAATGATTTC 
   
IL-10**  Forward 
Reverse 
Probe 
GACATCAAGGAGCACGTGAACTC 
CAGGGCAGAAATCGATGACA 
AGCCTCACTCGGAGGGTCTTCAGCTT 
   
TNF-α Forward 
Reverse 
Probe 
TTACCGAATGCCTTCCAGTCAAT 
GGGCTACAGGCTTGTCACT 
CCAGACACTCAGATCAT 
* (Nerren, 2008) 
** J. Nerren, unpublished data
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Statistical Analysis 
All data were analyzed as a randomized complete block design using the PROC 
MIXED procedure of SAS (SAS v 9.1; SAS Inst. Inc., Cary, NC).  Treatment, time, and 
their interaction were included in the model.  Main effects were considered significant 
when P ≤ 0.05 and a trend toward significance when P ≤ 0.10. 
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CHAPTER IV 
RESULTS AND DISCUSSION 
 
Physical Parameters 
No effects of treatment were observed on heart rate, respiratory rate, or rectal 
temperature (P = 0.77, P = 0.16, and P = 0.60 respectively; Table 2).  However, all three 
decreased over time (P < 0.01).  This change can be attributed to the young horses 
becoming acclimated to the repeated handling procedures, resulting in a diminished 
stress response.  This finding agrees with that of Palmer and Bertone (1994), who 
observed no changes in peripheral temperature, pulse rate, or respiratory rate in horses 
that received intra-articular injection of 0.125 ng, 0.17 ng, 0.25 ng, or 0.5 ng LPS.    
At 0 h post-injection, all horses were determined to be clinically sound (lameness 
score 0).  Lameness scores increased across all groups over the 24 h following LPS 
challenge, with peak scores ranging from 1 to 2, regardless of treatment (P < 0.01; Table 
3).  This observation demonstrates the necessity for studies utilizing repeated 
arthrocentesis to include a group of control animals so that effects of treatment are not 
confounded by changes associated with repeated arthrocentesis alone.   
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Additionally, the lameness scores of horses receiving any dosage of LPS 
injection were increased at 12 and 24 h post-injection compared to the control group (P ≤ 
0.05).  These data suggest that the effect of the endotoxin was sufficient to induce 
discomfort beyond that induced by arthrocentesis alone.  While lameness was still 
evident at the conclusion of the 24 h study, we predict that this would have been 
resolved within 48 h, as was the case in the Palmer and Bertone study (1994), which 
reported lameness scores ranging from 1 to 3 in the 36 h following LPS injection of up 
to 0.5 ng but all lameness was resolved by 48 h post-injection.   
Treatments did not affect joint circumference (P = 0.96); however, circumference 
increased 0.8 to 1.5 cm above baseline in all groups regardless of treatment (P < 0.05; 
Table 4).  Once again this observation can be attributed to the process of repeated 
arthrocentesis, and the merit of having a control group in similar studies is clearly 
warranted.  We expect that this mild joint effusion would have been resolved within 48 h 
post-injection, as was observed in the Palmer and Bertone study (1994) which elicited a 
similar increase in joint circumference of 1 to 1.5 cm at the LPS dosages up to 0.5 ng. 
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Table 2.  Least square means for heart rate (HR), respiration rate (RR), and rectal 
temperature (RT) by treatment across yearling Quarter Horses for a 24 h period in 
response to intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 ng, or 0 ng 
(control). 
Treatment 
  0 ng LPS 0.25 ng LPS 0.5 ng LPS SE 
HR (beats/min)    
 0 48.5
a,b,c
 46.5 48.5
a
 1.61 
 2 49.5
a
 45.5 48.5
a
 1.61 
 6 45.5
b,e
 45.5 46.5
a
 1.61 
 12 45.0
c,e
 44.5 42.5
b
 1.61 
 24 42.0
d,e
 43.0 41.5
b
 1.61 
RR (breaths/min)    
 0 19.0
a
 16.0
a,b
 17.5
a
 1.41 
 2 19.5
a
 16.0
a
 16.5
a
 1.41 
 6 14.5
b
 12.5
b,c
 13.0
b
 1.41 
 12 12.5
b
 11.0
c
 13.0
b
 1.41 
 24 12.5
b
 10.0
c
 11.0
b
 1.41 
RT (°C)    
 0 38.1
a
 37.9
a,b
 38.1
a,b
 0.14 
 2 38.1
a
 38.0
a,e
 38.1
a,b
 0.14 
 6 37.9
b
 37.9
b
 37.9
a
 0.14 
 12 38.2
a
 38.1
c,e
 38.1
b
 0.14 
 24 37.8
b
 37.7
d
 37.7
c
 0.14 
a-e
Within a column for a given parameter, means that do not have a common superscript 
differ (P ≤ 0.05). 
 
Table 3. Lameness scores (grading system 0-5, AAEP 1999) in yearling Quarter Horses 
over the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 
ng, 0.5 ng, or 0 ng (control).  
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 0.0
a
 0.8
b
 1.0
b
 1.0
b
 0.8
b
 0.22 
0.25 ng LPS 0.0
a
 1.7
b
 1.5
b
 1.7
†b
 2.0
†b
 0.22 
0.50 ng LPS 0.0
a
 1.2
b
 1.3
b
 1.7
†b
 1.7
†b
 0.22 
†Indicates significant difference within a column (P ≤ 0.05). 
a-cWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
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Table 4. Carpal circumference (cm) in yearling Quarter Horses over the 24 h period 
following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 ng, or 0 ng 
(control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 28.3a,b 28.8a 29.4b 29.7b 29.8b 0.66 
0.25 ng LPS 28.3a 28.5a 28.8a 29.4b 29.7b 0.66 
0.50 ng LPS 28.5a 29.0b 29.0b 29.3b 29.3b 0.66 
a-bWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
 
Circulating Leukocyte Population 
Similar studies have focused on biomarkers of inflammation located in the 
synovial fluid rather than peripheral blood.  Synovial fluid leukocyte data have been 
reported but to our knowledge, there are relatively few published accounts of leukocyte 
dynamics in the peripheral blood over the course of an intra-articular LPS challenge.  
The current study aimed to quantify and compare the total circulating leukocyte 
population and determine cellular differential in yearling horses following an intra-
articular LPS injection at different dosage levels.  No effects of LPS treatment were 
observed on the total leukocyte count or differential.   
Similarly, no changes in systemic leukocyte totals or differentials were observed 
when ponies received an intra-articular LPS injection of 0.02 μg/kg of bodyweight; 
however, peripheral blood was analyzed only at 0 and 8 h post-injection (Todhunter et 
al., 1996).  Hawkins et al. (1993) analyzed equine peripheral blood leukocyte counts at 
nine time intervals concluding at 144 h following intra-articular injection of 3 μg LPS 
and also reported no changes due to treatment.  These findings as well as those of the 
current study are in agreement with Palmer and Bertone (1994), who reported no 
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changes in total peripheral leukocyte count in any horse, regardless of intra-articular LPS 
dosage ranging from 0.125 ng to 5,000 ng.  Palmer and Bertone (1994) observed an 
alteration in peripheral blood leukocyte differential only at the 5,000 ng dose; however 
this is exponentially larger than the dosage levels (0.25 ng and 0.5 ng LPS) utilized in 
the current study.  It is likely that our LPS dosages were not large enough to induce a 
detectable deviation in systemic leukocyte dynamics.   
However, in the current study, total circulating leukocytes increased over time, 
regardless of treatment (P = 0.04; Table 5), with the highest values at 6 and 24 h post-
injection.  Similarly, an increase over time was observed in subpopulations of monocytes 
(P = 0.002; Table 6) and in platelets (P = 0.01; Table 7) by 24 h post-injection.  These 
observations further reinforce the conclusion that repeated sterile arthrocentesis alone is 
sufficient to induce physiological changes, including hematological parameters.  
Nevertheless, the magnitude of these changes is minor and mean effects are well within 
the accepted reference ranges.  A similar study found that 24 h was the most sensitive 
time to detect changes induced by repeated arthrocentesis in the equine midcarpal joint 
(White et al., 1989).  Thus, future studies might benefit from including sampling time 
points beyond 24 h to further characterize these changes and identify the duration of the 
response until return to baseline values.    
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Table 5. Blood leukocyte count (cells × 1,000/μl) in yearling Quarter Horses over the 24 
h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 ng, 
or 0 ng (control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 9.8 9.6 9.8 9.6 10.4 0.95 
0.25 ng LPS 10.3a,b 10.2a 11.5c 10.9a,b 10.9a,c 0.95 
0.50 ng LPS 10.5 11.1 11.1 11.2 10.7 0.95 
a-cWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
 
 
Table 6. Blood monocyte count (%) in yearling Quarter Horses over the 24 h period 
following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 ng, or 0 ng 
(control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 1.2
a,b
 1.0
a
 0.6
a,b
 1.4
a,b
 2.8
b
 0.81 
0.25 ng LPS 1.4
a
 1.4
a
 1.4
a
 1.1
a
 3.4
b
 0.81 
0.50 ng LPS 1.7
a,b
 1.2
a
 1.2
a,b
 0.8
a
 3.0
b
 0.81 
a-bWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
 
 
Table 7. Blood platelet count (cells × 1,000/μl) in yearling Quarter Horses over the 24 h 
period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 ng, or 
0 ng (control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 217a,b,c 258a,b 202c 242a,b,c,d 275d 27 
0.25 ng LPS 231a 234a,b 225a,b 253a,b 280b 27 
0.50 ng LPS 242a,b 245a,b 219a,b 210a 265b 27 
a-dWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
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Cytokine Gene Expression 
Relative gene expression of IL-1β, IL-6, IL-8, IL-10, and TNF-α in the peripheral 
blood following an intra-articular LPS challenge was quantified using real-time PCR.  
Data were analyzed using the equation,  
target amount = 2
-ΔΔC
T, 
where ΔΔCt = (CT,target – Ct,B2M)Time x – (Ct,target – Ct,B2M)Time 0. 
Time x is post-injection hour 2, 6, 12, or 24 and Time 0 represents the 1X expression of 
the target gene normalized to B2M.   
Interleukin-1β 
No treatment effects were observed on IL-1β (P = 0.90); however, an effect of 
time was observed (P = 0.04; Table 8). 
 
Table 8. Relative systemic gene expression
a
 of IL-1β in yearling Quarter Horses over 
the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 
0.5 ng, or 0 ng (control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 1.00
b
 0.99
b
 1.46
b,c
 1.93
c
 1.44
b,c
 0.24 
0.25 ng LPS 1.00
b
 1.55
c,d
 1.30
b,d
 1.39
b,d
 1.54
b,d
 0.22 
0.50 ng LPS 1.00 1.32 1.45 1.41 1.25 0.24 
a
Data were normalized to the house keeping gene B2M and calibrated to baseline 
expression (time 0).   
b-dWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
 
Interleukin-6 
Treatment did not affect  IL-6 expression (P = 0.18); however, an effect of time 
was observed (P = 0.002; Table 9). 
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Table 9. Relative systemic gene expression
a
 of IL-6 in yearling Quarter Horses over the 
24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 
ng, or 0 ng (control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 1.00 0.83 0.76 0.75 0.79 0.15 
0.25 ng LPS 1.00
b
 1.27
c
 0.99
b
 0.91
b
 1.36
c
 0.13 
0.50 ng LPS 1.00
d,e,f
 1.19
b,d
 0.78
c,f
 0.87
c,e
 1.20
b,d
 0.15 
a
Data were normalized to the house keeping gene B2M and calibrated to baseline 
expression (time 0).   
b-fWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
 
Interleukin-8 
No treatment effects were observed on IL-8 (P = 0.24), but time did affect 
expression (P = 0.01; Table 10). Interleukin-8 was the only cytokine to surpass a 2-fold 
change in expression, which is conventionally considered the threshold for meaningful 
alterations in gene expression.  This finding may reflect the recruitment of 
polymorphonuclear (PMN) leukocytes, which secrete large quantities of IL-8.  As a 
chemokine, IL-8 stimulates and regulates migration of leukocytes from the blood to the 
tissues.  Its production is enhanced by IL-1 and TNF-α (Lipsky et al., 1989), thus it is 
possible that slight increases in IL-1 and TNF-α expression acted synergistically to 
amplify IL-8 gene expression in the peripheral blood in response to repeated 
arthrocentesis.  Future investigators may consider separateing PMN cells and peripheral 
blood mononuclear cells to explore cytokine expression from distinct subpopulations 
rather than the total circulating leukocyte population, as reported here.  
While statistically insignificant, IL-8 appears to be the most responsive to 
repeated arthrocentesis of the cytokines analyzed here and may be considered for future 
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studies which utilize peripheral blood cytokines as markers of inflammatory response.  
Increases in synovial fluid cytokine expression or immunoreactivity in response to small 
amounts of LPS injection have been reported (Hawkins et al., 1993; Todhunter et al., 
1996; Bertone et al., 2001).  This suggests that the response to intra-articular endotoxin 
injection is more readily detected locally within the synovial fluid.     
 
Table 10. Relative systemic gene expression
a
 of IL-8 in yearling Quarter Horses over 
the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 
0.5 ng, or 0 ng (control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 1.00
b
 1.90
b
 3.63
b
 8.87
c
 4.62
b
 1.66 
0.25 ng LPS 1.00 1.52 0.97 2.43 1.53 1.53 
0.50 ng LPS 1.00 1.16 1.19 1.63 1.26 1.66 
a
Data were normalized to the house keeping gene B2M and calibrated to baseline 
expression (time 0).   
b-cWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
 
Interleukin-10 
Treatment did not affect  IL-10 expression (P = 0.48).  However, trends toward 
both a time effect and a treatment x time interaction were observed (P = 0.08 and P = 
0.07, respectively; Table 11). 
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Table 11. Relative systemic gene expression
a
 of IL-10 in yearling Quarter Horses over 
the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 
0.5 ng, or 0 ng (control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 1.00 0.96 1.02 0.85 1.06 1.10 
0.25 ng LPS 1.00
b
 1.36
c
 1.04
b
 0.96
b
 0.93
b
 0.09 
0.50 ng LPS 1.00 1.15 1.08 1.10 1.15 0.10 
a
Data were normalized to the house keeping gene B2M and calibrated to baseline 
expression (time 0).   
b-cWithin a row, means that do not have a common superscript differ (P ≤ 0.05). 
 
Tumor Necrosis Factor-α 
No treatment effects were observed on TNF-α (P = 0.71); however, time 
influenced expression (P = 0.01; Table 12).   
 
Table 12. Relative systemic gene expression
a
 of TNF-α in yearling Quarter Horses over 
the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 
0.5 ng, or 0 ng (control).   
Treatment  Hour    
 0 2 6 12 24 SEM 
Control 1.00 1.08 1.31 1.14 1.19 0.17 
0.25 ng LPS 1.00
b
 1.36
b,d
 1.35
b,d
 1.55
c,d
 1.04
b
 0.16 
0.50 ng LPS 1.00
b
 1.17
b,d
 1.27
b,d
 1.52
c,d
 1.08
b
 0.17 
a
Data were normalized to the house keeping gene B2M and calibrated to baseline 
expression (time 0).   
b-d
Within a row, means that do not have a common superscript differ (P ≤ 0.05). 
 
Intravenous infusion of LPS has been previously shown to up-regulate gene 
expression of inflammatory cytokines including IL-1α, IL-1β, IL-6, IL-8, and TNF-α in 
horses, while expression levels remained at baseline for saline-treated control horses 
(Nieto et al., 2009).  These findings confirm that LPS is a potent agonist for inducing 
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inflammatory cytokine release.  It is possible that the low response to LPS in the current 
study may be attributed to the intra-articular route of administration.  The associated 
inflammatory response might have been limited to local recruitment of leukocytes within 
the synovial fluid, which would account for the failure to detect a pronounced systemic 
response.   
Synovial Fluid Biomarkers    
 A concurrent study analyzed markers of inflammation and articular cartilage 
metabolism in synovial fluid extracted at 0, 2, 6, 12, and 24 h (Lucia et al., 2011).  Lucia 
et al. (2011) detected no changes in collagenase cleavage neopeptide, a marker of 
catabolic type II cartilage metabolism; however, both prostaglandin E2 (a critical 
inflammatory mediator) and carboxypeptide (an established indicator of anabolic type II 
cartilage turnover) were linearly influenced by treatment, with concentrations increasing 
with LPS dosage (P ≤ 0.01).  This observation indicates that a difference of only 0.25 ng 
LPS was successful in inducing dosage-dependent effects in a young horse model.  
Further investigation with more than 2 dosage levels would be beneficial in identifying 
the most appropriate level of intra-articular LPS injection for the young horse.  In 
addition, all three biomarkers were influenced by time (P ≤ 0.01; Lucia et al., 2011), 
further suggesting a role of repeated arthrocentesis in modifying physiological 
parameters.     
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CHAPTER V 
SUMMARY 
 
 Previous work has established LPS as a useful model for inducing temporary 
inflammation in the mature equine for the purpose of investigating the progression of 
joint disease.  However, little research has been devoted to developing an appropriate 
model for use in the young horse.  With many athletic competitions limited to horses 
during their 3-year-old years, the industry is requiring horses to undergo rigorous 
training regimens at a young age, prior to skeletal maturity.  Thus, investigation into a 
model of acute inflammation for this stage of musculoskeletal development is clearly 
warranted.  In addition, the potential for a systemic effect of the inflammatory agent has 
been given little attention in previous studies and merits exploration.  The existence of 
such an effect would produce confounding results and may affect conclusions drawn 
from similar studies which use the common approach of employing a saline-injected 
contralateral joint as the control.   
 The results of the current study indicate that a singular intra-articular injection of 
0.25 ng or 0.50 ng LPS did not alter the total circulating leukocyte population or 
differential in yearling horses.  However, an effect of time was observed in total 
leukocytes as well as in cellular subpopulations of monocytes and platelets.  This 
response is likely due to the repeated arthrocentesis procedure.  Similarly, intra-articular 
injection of 0.25 ng or 0.50 ng LPS did not affect the expression of five cytokines which 
are crucial to the inflammatory cascade.  Once again an effect of time was observed, 
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indicating that the repeated arthrocentesis alone was sufficient to induce mild changes in 
expression levels which were similar across all groups.  Increased concentrations of IL-8 
suggest possible recruitment of PMN leukocytes in response to arthrocentesis.  Future 
studies may benefit from investigating the use of alternative biomarkers of inflammation 
in the peripheral blood and synovial fluid which may prove more sensitive to 
physiological changes.  
 From these results, we conclude that performing repeated arthrocentesis on a 
particular joint likely stimulates a mild inflammatory response, inducing effects which 
can be manifested systemically.  Including a negative control might be beneficial to 
establish physiological normal values for the parameters measured.  Future studies of a 
similar nature should utilize a separate group of control animals to eliminate any 
confounding effects of treatment and arthrocentesis.   
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APPENDIX A 
DIET 
Table A.1 Nutrient Composition (DM) of Diet Fed to Yearling Quarter Horses. 
 
Item Pelleted concentrate
1
 Hay
2
 
DM, % 87.76  91.34 
CP, % 17.60  8.90 
ADF, % 11.39  33.45 
NDF, % 23.79  59.71 
Ca, % 0.83  0.37 
P, % 0.68  0.14 
K, % 1.37  1.10 
Mg, % 0.33  0.19 
Na, % 0.21  0.09 
S, % 0.38  0.24 
Al, ppm 170.00  457.00 
Co, ppm 1.53  1.02 
Cu, ppm 53.20  9.28 
Fe, ppm 261.00  704.00 
Mn, ppm 128.00  33.70 
Mo, ppm 1.44  2.03 
Zn, ppm 110.00  29.20 
DE, Mcal/lb 1.52  1.15 
 
1
 Commercially prepared pelleted concentrate (Producers 14% Horse Pellet, Producer’s 
Cooperative Association, Bryan, TX). 
2
 Coastal Bermudagrass (Cynodon dactylon). 
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APPENDIX B 
PHYSICAL PARAMETERS 
 
Figure B.1  Lameness scores (grading system 0-5, AAEP 1999) in yearling Quarter 
Horses over the 24 h period following intra-articular lipopolysaccharide (LPS) injection 
of 0.25 ng, 0.5 ng, or 0 ng (control).  
 
 
 
 
Figure B.2  Carpal circumference (cm) in yearling Quarter Horses over the 24 h period 
following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 ng, or 0 ng 
(control). 
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APPENDIX C 
LEUKOCYTES 
 
Figure C.1  Blood leukocyte count (cells × 1,000/μl) in yearling Quarter Horses over  
the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 
0.5 ng, or 0 ng (control). 
 
 
 
Figure C.2  Blood monocyte count (%) in yearling Quarter Horses over the 24 h period 
following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 ng, or 0 ng 
(control). 
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Figure C.3  Blood platelet count (cells × 1,000/μl) in yearling Quarter Horses over the 
24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 0.5 
ng, or 0 ng (control). 
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APPENDIX D 
GENE EXPRESSION 
 
Figure D.1  Relative systemic gene expression of IL-1β in yearling Quarter Horses over 
the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 
0.5 ng, or 0 ng (control). 
 
 
 
Figure D.2  Relative systemic gene expression of IL-6 in yearling Quarter Horses over 
the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 ng, 
0.5 ng, or 0 ng (control). 
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Figure D.3  Relative systemic gene expression of IL-8 in yearling Quarter Horses  
over the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 
ng, 0.5 ng, or 0 ng (control). 
 
 
 
Figure D.4  Relative systemic gene expression of IL-10 in yearling Quarter Horses  
over the 24 h period following intra-articular lipopolysaccharide (LPS) 
injection of 0.25 ng, 0.5 ng, or 0 ng (control). 
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Figure D.5  Relative systemic gene expression of TNF-α in yearling Quarter Horses 
over the 24 h period following intra-articular lipopolysaccharide (LPS) injection of 0.25 
ng, 0.5 ng, or 0 ng (control). 
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